ELVNbenzinga

Enliven Therapeutics Announces Updated Data From Phase 1 ENABLE Clinical Trial Evaluating ELVN-001 In Patients With CML In Abstract Accepted For Oral Presentation At EHA 2025 Congress

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on May 14, 2025 by benzinga